JP2022524692A5 - - Google Patents
Info
- Publication number
- JP2022524692A5 JP2022524692A5 JP2021539095A JP2021539095A JP2022524692A5 JP 2022524692 A5 JP2022524692 A5 JP 2022524692A5 JP 2021539095 A JP2021539095 A JP 2021539095A JP 2021539095 A JP2021539095 A JP 2021539095A JP 2022524692 A5 JP2022524692 A5 JP 2022524692A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- domain
- tcrβv
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788497P | 2019-01-04 | 2019-01-04 | |
| US62/788,497 | 2019-01-04 | ||
| US201962803893P | 2019-02-11 | 2019-02-11 | |
| US62/803,893 | 2019-02-11 | ||
| PCT/US2020/012162 WO2020142672A2 (en) | 2019-01-04 | 2020-01-03 | Anti-tcr antibody molecules and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524692A JP2022524692A (ja) | 2022-05-10 |
| JP2022524692A5 true JP2022524692A5 (enExample) | 2023-03-06 |
| JP7700039B2 JP7700039B2 (ja) | 2025-06-30 |
Family
ID=71407087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539095A Active JP7700039B2 (ja) | 2019-01-04 | 2020-01-03 | 抗ｔｃｒ抗体分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220064255A1 (enExample) |
| EP (1) | EP3906057A4 (enExample) |
| JP (1) | JP7700039B2 (enExample) |
| CN (1) | CN113543807A (enExample) |
| AU (2) | AU2020204686A1 (enExample) |
| CA (1) | CA3125345A1 (enExample) |
| GB (1) | GB2595980B (enExample) |
| WO (1) | WO2020142672A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| CN113874400B (zh) | 2019-03-11 | 2025-02-07 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| JP7590430B2 (ja) * | 2019-11-14 | 2024-11-26 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| AU2020416273A1 (en) * | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US20230285586A1 (en) * | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20230346966A1 (en) * | 2020-07-23 | 2023-11-02 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| CA3190987A1 (en) * | 2020-08-10 | 2022-02-17 | Janssen Biotech, Inc. | Materials and methods for producing bioengineered virus specific lymphocytes |
| US12448449B2 (en) | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| AU2021339754A1 (en) * | 2020-09-11 | 2023-05-25 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| US20220089737A1 (en) * | 2020-09-11 | 2022-03-24 | Janssen Biotech, Inc. | Multi-specific immune targeting molecules and uses thereof |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| JP2026501572A (ja) * | 2022-12-27 | 2026-01-16 | イェール ユニバーシティー | Ｔｃｒ－ｖｂｅｔａ特異的治療用分子、及びその使用 |
| WO2024140981A1 (zh) * | 2022-12-30 | 2024-07-04 | 上药生物治疗（香港）有限公司 | 细胞原位分泌抗体及其用途 |
| WO2024197082A2 (en) * | 2023-03-21 | 2024-09-26 | Marengo Therapeutics, Inc. | Tcr targeting molecules and uses thereof |
| AU2024240821A1 (en) | 2023-03-23 | 2025-11-06 | Bodhi Bio Llc | Compositions and methods for antigen-specific therapy |
| EP4704897A1 (en) * | 2023-04-27 | 2026-03-11 | Marengo Therapeutics, Inc. | Combination therapies using molecules binding to tcr |
| WO2025050088A1 (en) * | 2023-08-31 | 2025-03-06 | Adaptive Biotechnologies Corporation | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis |
| WO2025051339A1 (en) * | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| WO2026011097A1 (en) * | 2024-07-03 | 2026-01-08 | Yale University | Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof |
| CN120064640B (zh) * | 2025-01-15 | 2026-01-23 | 中牧实业股份有限公司 | 一种猪细小病毒vp2双抗体夹心定量检测试剂盒及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| JPH0787994A (ja) * | 1993-04-30 | 1995-04-04 | Sumitomo Electric Ind Ltd | Ｔ細胞抗原受容体Ｖβ２２に対するモノクローナル抗体及びその製造方法 |
| IL125747A0 (en) * | 1996-10-04 | 1999-04-11 | Univ Jefferson | T cells mediating an immune response and methods of use |
| CA2625222A1 (en) * | 2005-10-11 | 2007-04-19 | Domantis Limited | Antibody polypeptide library screening and selected antibody polypeptides |
| US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| SG10201913680PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| PT3294768T (pt) * | 2015-05-13 | 2019-11-05 | Ablynx Nv | Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta |
| US20180256716A1 (en) * | 2015-06-01 | 2018-09-13 | Medigene Immunotherapies Gmbh | T-cell receptor specific antibodies |
| CN116334205A (zh) * | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| AU2017363311A1 (en) * | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2020010250A2 (en) * | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
-
2020
- 2020-01-03 AU AU2020204686A patent/AU2020204686A1/en not_active Abandoned
- 2020-01-03 WO PCT/US2020/012162 patent/WO2020142672A2/en not_active Ceased
- 2020-01-03 CN CN202080018799.0A patent/CN113543807A/zh active Pending
- 2020-01-03 GB GB2109794.4A patent/GB2595980B/en active Active
- 2020-01-03 EP EP20736073.6A patent/EP3906057A4/en active Pending
- 2020-01-03 JP JP2021539095A patent/JP7700039B2/ja active Active
- 2020-01-03 CA CA3125345A patent/CA3125345A1/en active Pending
-
2021
- 2021-07-02 US US17/366,638 patent/US20220064255A1/en not_active Abandoned
-
2025
- 2025-06-20 AU AU2025204695A patent/AU2025204695A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10918667B2 (en) | Modified cell expressing therapeutic agent and uses thereof | |
| US20220265721A1 (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
| TWI862870B (zh) | 嵌合抗原受體療法t細胞擴增動力學及其用途 | |
| JP2020532954A5 (enExample) | ||
| JP7524465B2 (ja) | 免疫細胞機能の改善 | |
| JP7690597B2 (ja) | 免疫細胞機能の改善 | |
| KR20260013488A (ko) | 면역 이펙터 세포 및 이의 용도 | |
| TW202604968A (zh) | 多肽系統 | |
| EP4577234A1 (en) | Improving immune cell function | |
| HK40011995A (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |